47 Objective: To evaluate intraperitoneal (IP) tumor engraftment, metastasis and growth in 48 a pre-clinical murine epithelial ovarian cancer (EOC) model using both transabdominal 49 ultrasound (TAUS) and bioluminescence in vivo imaging system (IVIS).
6 137 debilitating ascites development as outlined in the above protocol, mice also reached 138 humane endpoint if ruffled fur, reduced mobility, or hunched body posture was 139 observed. Upon reaching humane endpoint criteria, mice were immediately euthanized 140 by CO2 asphyxiation and cervical dislocation. No animals were found dead before 141 meeting endpoint criteria in this study. All researchers participating in animal studies 142 were appropriately trained by veterinary technicians or skilled lab personnel following 143 approved IACUC guidelines.
144 The surgical specimens used to generate the PDX model were obtained with permission 145 from the Institutional Review Board of the Cleveland Clinic Foundation under IRB#18-062
146 Gynecologic Oncology Tissue Collection. Per IRB#18-062 all specimens were collected 147 after written informed consent was obtained from the patient. Tissue collected was frozen 148 and stored and when available, live tissue procured to establish patient derived 149 xenografts.
150 Mouse Xenografts 151 Ten female C57Bl/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME) 152 at 6 weeks of age. After two weeks of acclimation, mice underwent IP injection of 300uL 153 of either 5x10 6 ID8-luc (n=5) or ID8-VEGF (n=5) cells. All mice met endpoint criteria by 154 58 days post cell injection and no mice were removed from the study prior to meeting 155 endpoint criteria. 178 3D IVIS Imaging.
179 Upon endpoint, bioluminescence and x-ray images were taken using the IVIS Spectrum The smallest tumor short and long axis measurements detected at 7 days were 211 1.74mm and 2.23mm, respectively. The lowest recorded tumor volume was 4.17mm.
212 Ascites was detected as early as 21 days. Tumor volume detected via TAUS over time 
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In clinical practice, transabdominal and transvaginal US remain gold-standard for 320 the initial assessment of gynecologic pathology, including ovarian tumors. TAUS is non-321 invasive and cost-effective with low risk to the patient. In this study, we demonstrate that 322 this same imaging modality can be applied to mouse xenografts. Based on these results, 323 we have adopted TAUS as a method to monitor tumor growth and treatment response in 324 EOC preclinical studies in both syngeneic and PDX models with excellent success and 325 reproducibility. One limitation of this model is the need for mouse anesthesia during 326 TAUS. In this series, anesthesia and TAUS were well tolerated by the mice with no 327 adverse intra-anesthesia events or mortalities related to the procedure. Despite this, to 328 the best of our knowledge, this study represents the first publication assessing the 329 feasibility of TAUS for preclinical murine models of EOC in parallel with IVIS imaging.
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In conclusion, TAUS shows promise in the detection of tumor growth and 16 332 allows for detailed measurements of tumors and metastatic implants, ascites and is more 333 sensitive than IVIS imaging. 
